Moderna begins next phase of Omicron-specific booster trial as study finds that antibodies remain durable despite 6-fold drop over 6 months

Moderna announced Wednesday that the first participant has been dosed in the company's Phase 2 clinical trial of a coronavirus vaccine booster shot that is specific to the Omicron variant.

Related Keywords

Moderna Covid ,Dave Montefiori ,William Schaffner ,National Foundation For Infectious Diseases ,Emory University ,National Institutes Of Health ,Warnermedia Company ,Duke University Department Of Surgery ,Us Centers For Disease ,Pfizer ,University Of Maryland School Medicine ,Vanderbilt University ,Cable News Network Inc ,Baylor College Of Medicine ,Duke University ,Fred Hutchinson Cancer Research Center ,New England Journal ,Disease Control ,Baylor College ,Maryland School ,National Institutes ,National Foundation ,Infectious Diseases ,News Network ,Companies ,Ourt Trials ,Aw And Legal System ,Moderna ,Rial And Procedure ,Coronavirus ,Iseases And Disorders ,Ealth And Medical ,Mmunology ,Ife Forms ,Edical Fields And Specialties ,Icroscopic Life ,Respiratory Diseases ,Viruses ,Ommunicable Disease Control ,Public Health ,Accination And Immunization ,Booster Shot ,Ntibody ,Moderna Covid 19 ,Medicine ,Harmacology ,Virus ,Protection ,Trial ,